Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.
Medical Device Network on MSN
Prodeon Medical’s BPH implant gains FDA clearance
In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score improvements.
The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with reassurance, ...
Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...
For men with benign prostate hyperplasia, aquablation provides temporary benefits for ejaculation and continence at three months, while holmium laser enucleation of the prostate (HoLEP) has superior ...
PHILADELPHIA (WPVI) -- Benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland, is the most common benign tumor found in men. BPH produces symptoms by obstructing the flow ...
A Dec. 29 Instagram post (direct link, archive link) shows a woman speaking over a screenshot of an X post that claims to share news about Israeli Prime Minister Benjamin Netanyahu. "BREAKING: Head of ...
Morning Overview on MSN
Study finds microplastics in 90% of prostate cancer tumors
Researchers at NYU Langone Health have detected tiny plastic fragments in nine out of 10 prostate cancer tumors examined, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results